A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Inclusion Criteria:

• Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

• Insulin naïve subjects (Allowed are: previous short term insulin treatment up to 14days; treatment during hospitalisation or during gestational diabetes is allowed forperiods longer than 14 days)

• Current treatment: metformin monotherapy or metformin in any combination with aninsulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV)inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3months prior to randomisation (Visit 2) with the minimum doses stated: metformin:alone or in combination (including fixed combination) 1500 mg daily, or maximumtolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea orglinide): minimum half of the daily maximal dose according to local labelling, DPP-IVinhibitor: minimum 100 mg daily or according to local labelling,alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose ormaximum tolerated dose

• HbA1c (glycosylated haemoglobin) 7.0-10.0% (both inclusive) by central laboratoryanalysis

• BMI (Body Mass Index) below or equal to 40.0 kg/m^2

Exclusion Criteria:

• Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptoragonists within the last 3 months prior to Visit 1 (screening)

• Anticipated change in concomitant medication known to interfere significantly withglucose metabolism, such as systemic corticosteroids, beta-blockers, MAO (monoamineoxidase) inhibitors

• Cardiovascular disease within the last 6 months prior to Visit 1 (screening) definedas stroke; decompensated heart failure NYHA (New York Heart Association) class III orIV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graftor angioplasty

• Any clinically significant disease or disorder, except for conditions associated withtype 2 diabetes mellitus, which in the Investigator's opinion could interfere with theresults of the trial

• Previous participation in this trial. Participation is defined as randomised.Re-screening of screening failures is allowed only once within the limits of therecruitment period

• Known or suspected hypersensitivity to trial product(s) or related products